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Differentiation and Expansion of Functional Human
NK Cells from CD341 Cord Blood Hematopoietic
Progenitor Cells
Rose C. Beck,1 Mallika Padival,1 David Yeh,1 Justine Ralston,1
Kenneth R. Cooke,2 John B. Lowe1Notch receptor signaling is required for T cell development, but its role in natural killer (NK) cell development
is poorly understood. We compared the ability of the 5 mammalian Notch ligands (Jagged1, Jagged2, Delta1,
Delta3, or Delta4) to induce NK cell development from human hematopoietic progenitor cells (HPCs).
CD341 HPCs were cultured with OP9 stromal cell lines transduced with 1 of the Notch ligands or with
OP9 stromal cells alone, in the presence of IL-7, Flt3L, and IL-15. Differentiation and expansion of
CD561CD32 cells were greatly accelerated in the presence of Jagged2, Delta-1, or Delta-4, versus culture
in the absence of ligand or in the presence of Jagged1 or Delta3. At 4 weeks, cultures containing Jagged2,
Delta1, or Delta4 contained 80% to 90% NK cells, with the remaining cells being CD331myelogenous cells.
Notch-inducedNK (N-NK) cells resembledCD56bright NK cells in that theywereCD162, CD942, CD1171,
and killer immunoglobulin-like receptors (KIR2). They also expressed NKp30, NKp44, NKp46, 2B4, and
DNAM-1, with partial expression of NKG2D. The N-NK cells displayed cytotoxic activity against the K562
and RPMI-8226 cell lines, at levels similar to activated peripheral blood (PB) NK cells, although killing of Daudi
cells was not present. N-NK cells were also capable of interferon (IFN)-g secretion. Thus, Notch ligands have
differential ability to induce and expand immature, but functional, NK cells from CD341 HPCs. The use of
Notch ligands to generate functional NK cells in vitro may be significant for cellular therapy purposes.
Biol Blood Marrow Transplant 15: 1026-1037 (2009)  2009 American Society for Blood and Marrow TransplantationKEY WORDS: Natural killer cell, Notch, Umbilical cord blood, Cell therapyINTRODUCTION
Natural killer (NK) cells are lymphocytes that arise
from common lymphogenous progenitor cells during
hematopoiesis. Unlike T and B lymphocytes, however,
NK cells do not express rearranged antigen receptors
and are therefore considered part of the innate
immune system. NK cells have the unique ability to
kill tumor or virally infected cells without prior immu-
nization. Another major function of NK cells is to
secrete cytokines, such as interferon (IFN)-g and
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6/j.bbmt.2009.06.002inflammatory immune responses and also influence
adaptive immunity. Human NK cells are defined as
CD561CD32 lymphocytes, which morphologically
are indistinguishable from CD81 granular T cells.
The circulating pool of NK cells in humans
consists of 2 populations: CD56dimCD16bright and
CD56brightCD16dim. The former population is
predominant (.95% of circulating NK cells), has
more cytotoxic than cytokine-producing activity, and
may represent a mature NK cell population, which
evolves from CD56brightCD16dim cells [1]. Accord-
ingly, CD56bright NK cells express CD117, higher
levels of CD94 (which heterodimerizes with NKG2A
(Natural Killer Group 2, member A) or NKG2C to
form HLA-E recognition receptors), and CCR7,
which may allow for NK cell trafficking to lymph
nodes [2]. In contrast, CD56dim NK cells express
higher levels of killer immunoglobulin-like receptors
(KIRs) and the natural cytotoxicity receptors (NCRs),
which include NKp30, NKp44, and NKp46, impor-
tant for tumor cell recognition and lysis. CD56dim
NK cells downregulate expression of CCR7 and ex-
press CXCR1, which binds IL-8 and is postulated to
Biol Blood Marrow Transplant 15:1026-1037, 2009 1027Notch Ligands and Human NK Cell Differentiationaid in the CD56dim NK cell response to inflammation
[2]. Members of the KIR family are critical for trans-
mission of inhibitory signals to NK cells upon binding
of self-MHC class I molecules, thus mediating self-tol-
erance of CD56dimNK cells. Expression of CD16, also
known as the low-affinity IgG Fc receptor, also allows
CD56dim NK cells to mediate antibody-dependent
cell-mediated cytotoxicity in the presence of the anti-
body specific to target cells. Both types of NK cells ex-
pressNKG2D, a homodimeric activating receptor that
binds stress-inducible ligands on tumor cells.
It has been traditionally postulated that human
NK cells develop in the bone marrow (BM), but recent
data suggest that NK cell precursors from the BMmay
migrate to secondary lymphogenous organs, where
maturation of NK precursors into CD56bright NK cells
can occur. The NK cell precursors identified in lymph
nodes have been divided into subsets based on expres-
sion of CD34, CD94, and CD117 [3-5]. In line with
this hypothesis, CD56bright NK cells are found prefer-
entially in lymph nodes and can express CD16, KIRs,
and NCRs, as well as acquire cytotoxic activity, upon
activation [6,7].
In vitro, bothmouse andhumanNKcells candiffer-
entiate from BM- or cord blood-derived hematopoietic
progenitor cells (HPCs) in the presence of cytokines
alone; these NK cells appear phenotypically immature
and resemble CD56bright cells [8]. Culture of HPCs in
the presence of both cytokines and stromal cells allows
for further maturation of NK cells, including acquisi-
tion of KIRs or the murine equivalent, the Ly49 recep-
tor family [9,10]. The signals mediated by stromal cells
to induce NK cell maturation are unknown, but 1 po-
tential signal may be from Notch ligands expressed by
stromal cells.
The evolutionarily conserved Notch receptor
pathway plays important roles in cell-fate decisions,
and is essential for T cell development [11]. In
vertebrates, 4 different Notch receptors, Notch 1-4,
may bind up to 5 known ligands, Jagged1, Jagged2,
Delta1,Delta3, andDelta4. Binding of differentNotch
ligands to distinct Notch receptors can variably influ-
ence T cell development [12-15]. In particular, the
Notch1:Delta4 interaction has been shown to have
greater capacity to induce murine T cell development
versus Notch binding of Delta1 [12]. Although T and
NK cells are postulated to derive from a common T/
NK precursor, the Notch1 receptor is not absolutely
required for NK cell development in vivo, as an induc-
ible Notch1-knockout mouse has normal levels of
NK1.11 cells [16]. The importance of signaling via
other Notch receptors in NK cell development is
unclear. In vitro, Notch signaling mediated by binding
of Jagged2, in the presence of cytokines important for
NKcell differentiation (IL-15or IL-2), inducesmurine
NK cell development from Lin-Sca11c-kit1 HPCs
[17], whereas Delta1 has recently been shown to causeNK cell differentiation from human CD341 HPCs
[18]. Thus, there is in vitro evidence that Notch signal-
ing can drive NK cell differentiation from the early
hematopoietic precursors.
To further define the capacity of Notch ligands to
modulate development of human NK cells, we deter-
mined the differential ability of the 5 differentNotch li-
gands found in vertebrates to induce NK cell
differentiation and expansion from CD341 HPCs iso-
lated from umbilical cord blood (UCB). In addition,
we analyzed the cell surface phenotype and function of
Notch-induced NK (N-NK) cells and compared these
characteristics to NK cells generated in vitro in the
absence ofNotch signaling, as well as toNK cells found
in normal adult peripheral blood (PB). N-NK cells dis-
play a predominantly immatureCD56bright surface phe-
notype, with no expression ofCD16, and the capacity to
secrete IFN-g.Unlike physiologicCD56brightNKcells,
however, they do not expressCD94 andhave onlymod-
erate levels of NKG2D expression. In addition, N-NK
cells lack the inhibitory receptors NKG2A and KIRs,
yet, they do express all 3 of the NCRs, NK-30,
NKp44, andNKp46, and are able to lyse hematopoietic
tumor cell lines in vitro.Thus, the receptor profile ofN-
NK cells is biased toward activating NK cell receptors.
Finally, the presence ofNotch ligand stimulatesmarked
expansion of NK cells fromHPCs, resulting in average
yields of 700 to 1100 NK cells per input cell.
The use of Notch ligands to generate large num-
bers of functional, inhibitory receptor-negative NK
cells may be useful for producing human NK cells
for cell therapy purposes, as infusion of allogeneic
NK cells is 1 strategy for tumor immunotherapy
[19,20]. The absence on N-NK cells of inhibitory
receptors (KIR and NKG2A), which recognize major
histocompatibility complex (MHC) class I antigens
would be advantageous in an allogeneic therapy set-
ting, circumventing the need for KIR:HLA ligandmis-
match between donor and recipient. Elucidation of the
ability of different Notch ligands to induce NK cell
differentiation and expansion, as well as evidence for
the functionality of N-NK cells, allow for more opti-
mal design of in vitro NK cell culture strategies for
cell therapy.METHODS
OP9 Cell Lines
The murine BM stromal cell line OP9 [21] was
transduced with 1 of 5 different Notch ligands in a bi-
cistronic message with green fluorescent protein
(GFP) in the vector Ret-10, to generate the lines
OP9-Jagged1, OP9-Jagged2, OP9-Delta1, OP9-
Delta3, and OP9-Delta4, as previously described
[22]. A control cell line, OP9-Ret-10, was transduced
with vector containing GFP alone. The OP9 cell lines
1028 Biol Blood Marrow Transplant 15:1026-1037, 2009R. C. Beck et al.were maintained in a-MEM with 20% fetal bovine
serum (FBS) and antibiotics.
Human Cells and OP9 Coculture
PB was obtained from healthy volunteers via the
Stem Cell Core Facility of the Case Comprehensive
Cancer Center via institutional review board (IRB)-ap-
proved protocols, and NK cells were isolated from the
mononuclear cell (MNC) fraction using a negative se-
lection kit from Miltenyi Biotec (Bergisch Gladbach,
Germany). For isolation of CD341HPCs, UCB units
were obtained from the labor and delivery unit at Uni-
versity Hospitals Case Medical Center under an IRB-
approved protocol. After ficoll gradient, CD341 cells
were isolated from UCB MNCs using the CD34
MACS system from Miltenyi Biotec. Flow cytometric
analysis of purified CD341 cells routinely demon-
strated $97% purity. CD341 cells were used fresh
or cryopreserved for later use.
For coculture, 2 104 OP9 cells were seeded per
well in 12-well plates and allowed to adhere at least
4 hours at 37 C, after which time 2-2.5 104
CD341 UCB HPCs were plated onto the OP9 cells
in RPMI supplemented with 10% FBS and antibiotics.
Cells were cultured in the presence of recombinant
cytokines: hIL-7 (10 ng/mL), hFlt3 ligand (10 ng/
mL), and hIL-15 (10 ng/mL). In some initial experi-
ments, hIL-2 (25 ng/mL) was used in place of hIL-
15. When indicated, cultures were further stimulated
with hIL-12 and hIL-18, both used at 100 ng/mL.
All cytokines were purchased from R&D Systems
(Minneapolis, MN). Half of the media in the coculture
wells was changed twice weekly, with addition of fresh
cytokines. To prevent OP9 overgrowth, HPCs were
transferred to fresh OP9 monolayers weekly. After 2
weeks of coculture, the hematopoietic cells were split
in half onto new OP9 monolayers at least weekly, to
prevent overcrowding. Some cocultures were plated
and cultured in the presence of 10 mM of the
g-secretase inhibitor, L-685,458 (Sigma Aldrich, St.
Louis, MO) dissolved in DMSO [22].
Flow Cytometry
Cells were harvested from coculture at indicated
time points and were treated with human FcR blocking
reagent (Miltenyi Biotec) prior to antibody staining.
The following antihuman antibodieswere used for anal-
ysis: CD1a-PE, CD2-FITC, CD3-FITC, CD7-FITC,
CD11b (MAC-1)-FITC, CD11c-FITC, CD16-FITC
or -PE, CD18-FITC, CD19-FITC, CD33-PE, CD56-
FITC or -PE or -APC, CD62L(L-selectin)-PE, CD94-
FITC, CD117-PE, CD181(CXCR1)-FITC, CD244
(2B4)-PE, CD226 (DNAM-1)-FITC, CD314 (NKG-
2D)-FITC or -PE, ICAM-1-PE, and perforin (eBio-
science, San Diego, CA); CD335 (NKp46)-PE,
CD336 (NKp44)-PE, and CD337 (NKp30)-PE (Mil-tenyi Biotec); CD11a (LFA-1)-PE, NKG2A-PE,
and NKG2C-PE (R&D Systems); CD158a-PE and
CD158b-PE (Immunotech Beckman Coulter, Mar-
seille, France); and DX9 (BD Pharmingen, San Jose,
CA). KIR expression was determined by combining
the CD158a, CD158b, and DX9 antibodies, which
will detect KIR2DL1/2/3, KIR2DS1/2/4, and
KIR3DL1 [23]. For analysis of perforin expression,
cells were fixed and permeabilized using FIX &
PERM (Invitrogen,Carlsbad,CA) according toman-
ufacturer’s protocol and stained with perforin and
CD56 antibodies. Three color (FITC, PE, and propi-
dium iodide [PI]) analysiswas performedonaFACScan
machine (Becton Dickinson, Franklin Lakes, NJ) and
analyzed with the manufacturer’s CellQuest software.
Alternatively, 4 color (FITC,PE, PI, andAPC) analysis
was performed using a FACSAria (Becton Dickinson)
and analyzed using BD’s FACScalibur software. All
analysis used forward and side scatter gating to exclude
OP9 cells and PI exclusion to gate on live cells.Cytotoxicity Assays and Inhibition of Perforin
TheCytotox 96nonradioactive cytotoxicity assay
(Promega, Madison WI) measures lactate dehydroge-
nase (LDH) release by colorimetric methods. After 3
or 4 weeks of coculture, harvested cells were analyzed
for percent CD561CD32 (effector, E) cells by flow
cytometry. For cells derived in the absence of Notch
ligand, because of the low level of CD561CD32 cells,
NK cell enrichment was performed via negative selec-
tion using anti-CD13 antibody (eBioscience) and goat-
antimouse IgG magnetic beads (Miltenyi Biotec).
Effector cells were plated in triplicate in 96-well
round-bottom plates with 1 or 1.5 104 target (T)
cells at indicated E:T ratios. After 4 hours at 37C,
plates were centrifuged and supernatant was collected
and assayed for LDH release according to manufac-
turer protocol. Percent specific lysis was calculated
using averaged absorbance values: [(experimental2E
spontaneous2T spontaneous)/(T maximum2T
spontaneous)] 100. The following human hemato-
poietic cell lines were used as target cells: Daudi,
Jurkat, RPMI-8226, and U266 (American Type Cul-
ture Collection, Manassas, VA); Jurkat, HL-60 (kind
gifts of Dr. Stanton Gerson); K562 (kind gift of
Dr. Clifford Harding).
For inhibition of perforin, E cells were pretreated
with either concanamycin-A (Sigma Aldrich) dissolved
in DMSO at indicated concentrations or DMSO for
1 hour at 37 C, then washed twice before use in the
cytoxicity assay.IFN-g ELISA
Supernatants were collected from cocultures and
analyzed for the presence of IFN-g using a standard
Biol Blood Marrow Transplant 15:1026-1037, 2009 1029Notch Ligands and Human NK Cell Differentiationsandwich ELISA containing capture and detection
antibodies from eBioscience.
Statistical Analysis
Significant differences between groups were
detected by 2-tailed Student’s t test.RESULTS
The Notch Ligands Jagged2, Delta1, and Delta4
Induce CD561CD32 Cells From Human HPCs
To determine whether Notch ligands are able to
generate NK cells from human HPCs, we used a BM
stromal cell line, OP9, transduced with each of the in-
dividual Notch ligands (Jagged1, J1; Jagged2, J2;
Delta1, D1; Delta3, D3; and Delta4, D4) in a bicis-
tronic message with GFP, resulting in the lines OP9-
J1, OP9-J2, OP9-D1, OP9-D3, and OP9-D4 [22]. A
control cell line, OP9-Ret-10, contained vector having
only the GFP sequence. Expression of transduced
Notch ligand by each OP9 line was proportional to
the expression of GFP, and flow cytometric analysis
demonstrated a range of green fluorescence intensity
from 0.9- to 2.5-fold versus OP9-Ret-10. CD341 cellsFigure 1. The Notch ligands Jagged2, Delta1, and Delta4 accelerate NK cell
cells (defined as CD561CD32) from CD341 HPCs is enhanced by coculture
expressing Jagged1 or Delta3 or containing vector (Ret-10) alone. All cultu
Data shown is from day 21 of coculture and represents the mean6 SD o
(N-NK) cells in IL-151 cultures increases over time, and peaks after 4 wee
(C) NK cell differentiation is inhibited by the presence of a gamma-secretase
the mean of 2 experiments.isolated from umbilical cord blood were cultured with
each cell line, in the presence of IL-7, Flt3L, and IL-
15. After 21 days in culture, the Notch ligands Jag-
ged2, Delta1, and Delta4 demonstrated the greatest
capacity for inducing NK cell development, as mea-
sured by percent CD561CD32 cells in the culture
(Figure 1A), with Jagged2 producing an average of
76% NK cells, Delta1, 67%, and Delta4, 70% NK
cells in the presence of IL-15. The non-NK cells in
the cultures containing Jagged2, Delta1, and Delta4
consisted of CD331 myelogenous cells and
CD71CD1a2 lymphogenous precursors, presumed
to be NK cell precursors because of the lack of
CD1a expression (Figure 2). In contrast, in the absence
of IL-15, Notch signaling via Jagged2, Delta1, and
Delta4 drove the development of T cell precursors, de-
fined as being positive for both CD7 and CD1a
(Figure 2A, and data not shown), in agreement with
prior observations [24] and with the established role
for Notch signaling in T cell development. Cultures
containing Jagged1 or Delta3 or without Notch ligand
in the presence of IL-15 consistently produced less
than 25% CD561CD32 cells at day 21 of culture;
these cultures consisted predominantly of CD331 cells
(Figure 2, and data not shown). Similar results for eachdifferentiation from human CD341 HPCs. (A) The development of NK
with OP9 cells expressing Jagged2, Delta1, or Delta4, versus OP9 cells
res contain IL-7 and Flt3-L plus IL-15 (black bars) or IL-2 (gray bars).
f at least 3 experiments. (B) The percentage of Notch-induced NK
ks. Data shown represent the mean6 SD of at least 3 experiments.
inhibitor (GSI), L-685,458, at day 21 of culture. Data shown represents
Figure 2. CultureofCD341HPCs in the presenceof IL-15 andNotch ligand drivesNKcell differentiation,withoutTorB cellmaturation. Flowcytometric
analysis of 4-week-old cultures containing the Notch ligand Delta4 and IL-15 demonstrate abundance of CD71CD561NK cells and no T cell precursors
(A), mature T cells (CD31; B), or B cells (CD191; C), whereas culture without IL-15 in the presence of Delta4 demonstrates predicted T cell precursors
(CD1a1CD71; A). CulturewithoutNotch ligand (RET-10) in thepresenceof IL-15demonstrates fewCD71NKcell precursors andCD561NKcells (A, B),
with mostly CD331 myelogenous cells and no development of Tor B cells (A-C). All cultures contained IL-7 and FltL. Data from cultures containing the
Notch ligands Jagged2 or Delta1 showed similar results to the Delta4 culture. Data shown is representative of at least 4 experiments.
1030 Biol Blood Marrow Transplant 15:1026-1037, 2009R. C. Beck et al.Notch ligand were seen when IL-2 was used in culture
instead of IL-15 (Figure 1, and data not shown). For
the remainder of the experiments, IL-15 was used to
drive NK cell differentiation in the cocultures.
The appearance of NK cells could be seen as
early as day 14 in culture (Figure 1B) and continued
to rise until day 28, at which time NK cells became
80% to 90% of total hematopoietic cells in cocultures
containing Jagged2, Delta1, or Delta4. The NK cells
continued to dominate cultures by day 42, but prolif-
eration decreased after day 28, and the culturesceased to proliferate between days 35-42 (data not
shown). No CD191 or CD31 cells were seen in any
culture condition at any time point (Figure 2).
The induction of CD561CD32 by Jagged2, Delta1,
orDelta4 was dependent on signaling via theNotch re-
ceptor, as the level of NK cell differentiation was
greatly reduced in the presence of a gamma-secretase
inhibitor (GSI), an inhibitor of Notch signaling
(Figure 1C). The presence of the GSI, however, failed
to abrogateNK cell differentiation in cultures contain-
ing OP9-Ret-10, indicating that the development of
Biol Blood Marrow Transplant 15:1026-1037, 2009 1031Notch Ligands and Human NK Cell DifferentiationNK cells in these cultures was not dependent onNotch
signaling.
In addition to inducing NK cell differentiation,
Notch signaling via ligation with Jagged2, Delta1, or
Delta4 also caused marked expansion of total NK
cell number, resulting in average yields of 700
(Delta1), 800 (Jagged2), or 1100 (Delta4) NK cells
per input cell on day 28 of culture, versus an average
yield of 200 NK cells per input cell in the absence of
Notch ligand (Figure 3).Figure 3. The Notch ligands Jagged2, Delta1, and Delta4 induce NK
cell expansion from human CD341 HPCs. The number of NK cells
(defined as CD561CD32) derived per single CD341 input cell at day
28 of culture in the presence of IL-15 is shown; each symbol represents
an individual experiment with the horizontal bar indicating the mean
(n5 5-7 independent experiments). P values generated by Student’s t
test are shown.The Surface Phenotype of N-NK Cells
Resembles, but is Distinct from, That of
Immature (CD56bright) NK Cells
We next determined the maturation stage of
N-NK cells by surface receptor expression. Flow cyto-
metric immunophenotyping was performed on the
NK cells in cultures containing Jagged2, Delta1, or
Delta4, and compared to that of NK cells developed
in the absence of Notch signaling or normal PB NK
cells (Table 1). N-NK cells had a predominantly im-
mature NK cell phenotype, with bright expression of
CD56, expression of CD117 and CD7, and very little,
if any, expression of CD16, CD94, and KIRs (Figures
2 and 4). The lack of CD94 expression corresponded
to an absence of detectable NKG2A and NKG2C ex-
pression (Figure 4), both of which form heterodimers
with CD94 to form receptors that mediate inhibitorTable 1. Surface Phenotype of Notch-Induced NK Cells (Day 28 of
Notch and Normal Peripheral Blood NK Cells*
OP9-J2 OP9-D1
Markers of NK cell maturity/lineage
CD16 3.3 ± 3.6 3.4 ± 1.7
CD94 8.4 ± 3.7 15.6 ± 8.3
CD117 94.8 ± 9.5 90.1 ± 11.2
CD11b 21.9 ± 13.0 18.7 ± 10.7
CD2 4.3 ± 6.0 4.3 ± 4.0
CD7 56.5 ± 12.8 57.1 ± 8.9
DNAM-1 55.9 ± 18.6 39.6 ± 24.0
2B4 99.3 ± 1.3 97.9 ± 2.6
Inhibitory NK receptors
NKG2A 1.6 ± 0.8 1.9 ± 1.2
KIR† 0.1 ± 0.1 0.2 ± 0.4
Activating NK receptors
NKG2C 0.2 ± 0.3 0.3 ± 0.2
NKG2D 31.2 ± 17.8 17.9 ± 15.0
NKp30 80.8 ± 21.4 76.3 ± 23.9
NKp44 47.8 ± 11.5 40.2 ± 11.9
NKp46 94.5 ± 5.1 90.4 ± 3.8
Adhesion molecules
CCR7 3.7 ± 2.9 2.5 ± 1.6
CXCR1 1.9 ± 2.8 1.7 ± 1.4
CD62L 52.7 ± 13.1 61.6 ± 11.4
ICAM-1 97.0 ± 3.1 96.1 ± 3.8
CD11a 55.1 ± 23.5 52.2 ± 23.8
CD18 83.7 ± 9.1 77.1 ± 8.4
NK indicates natural killer; KIR, killer immunoglobulin-like receptors.
*Numbers indicate percentage of CD56+CD32 cells positive for that antige
6 standard deviation. Data for PB NK is derived from 3 normal donors.
†Antibodies used also detect the activating receptors KIR2DS1, KIR2DS2, ansignals upon binding to HLA-E expressed by target
cells. Interestingly, N-NK cells expressed moderate
levels of the activating receptor NKG2D and high
levels of the NCRs NKp30, NKp44, and NKp46
(Figure 4). This was in contrast to NK cells found in
PB, which expressed only NKp30 and NKp46, andCulture), Compared to NK Cells Developed in the Absence of
OP9-D4 OP9-Ret-10 PB NK
3.8 ± 2.0 30.1 ± 9.8 97.1 ± 2.3
10.1 ± 10.2 51.6 ± 10.0 76.1 ± 12.0
91.2 ± 15.0 21.3 ± 25.1 5.9 ± 6.2
20.4 ± 9.5 68.2 ± 10.7 97.2 ± 1.5
5.5 ± 5.7 8.8 ± 4.2 80.8 ± 0.9
74.2 ± 9.5 25.6 ± 6.2 98.8 ± 1.1
67.0 ± 15.0 73.8 ± 12.1 84.2 ± 14.7
99.4 ± 0.8 91.4 ± 7.0 99.9 ± 0.2
2.4 ± 2.2 14.5 ± 6.4 23.2 ± 23.6
0.0 ± 0.0 0.4 ± 0.2 68.7 ± 15.4
0.1 ± 0.1 1.4 ± 1.8 19.2 ± 26.6
33.6 ± 26.5 45.1 ± 11.6 54.1 ± 1.8
65.2 ± 24.5 81.4 ± 7.2 91.5 ± 13.9
56.1 ± 15.0 21.9 ± 10.4 0.8 ± 1.1
93.3 ± 7.5 92.2 ± 2.2 82.4 ± 22.6
2.7 ± 1.2 3.2 ± 0.7 0.1 ± 0.1
1.3 ± 1.0 2.5 ± 1.0 71.9 ± 5.5
67.2 ± 19.8 75.0 ± 6.5 60.1 ± 23.5
95.1 ± 3.6 97.7 ± 1.3 97.2 ± 0.1
65.3 ± 21.7 71.2 ± 9.6 73.6 ± 17.8
78.8 ± 13.6 98.1 ± 0.8 100.0 ± 0.0
n and are expressed as the mean of 3 experiments using OP9 cells,
d KIR2DS4.
Figure 4. N-NK cells have a predominantly immature NK cell surface phenotype, but do express NKG2D and the natural cytotoxicity receptors,
NKp30, NKp44, and NKp46. Expression of NK cell markers was examined on gated CD561CD32 cells from 4-week-old cocultures containing Delta4
or no Notch ligand (RET-10). KIR expression was examined by an antibody cocktail (DX91CD158a1CD158b). Data from cultures containing the
Notch ligands Jagged2 or Delta1 showed similar results to the Delta4 culture. Data shown is representative of at least 4 independent experiments.
1032 Biol Blood Marrow Transplant 15:1026-1037, 2009R. C. Beck et al.NK cells developed in vitro in the absence of Notch li-
gand, which expressed low levels of NKp44 (Table 1).
NKp44 is an activation-induced receptor [7,25] and
the high expression of all 3 NCRs on N-NK cells
may indicate an activated state of these cells. Interest-
ingly, CCR7 was not expressed by N-NK cells,
although the adhesion ligands CD62L, CD11a, and
CD18 were (Table 1). N-NK cells also failed to
express high levels of CXCR1 and CD11b (Mac-1),
markers of mature, CD56dim peripheral blood NK
cells [1,4,5].
Both N-NK cells and NK cells derived in the
absence of Notch ligand have bright CD56 expression
and lack expression of more mature NK cell markers
(such as CD16, CD94, KIR, and Mac-1). However,
theNKcells derived in the absence ofNotch ligand dif-
fered from N-NK cells, having higher levels of CD94
and NKG2A and lower levels of CD11. These results
are consistent with a more mature phenotype, similar
to that described in published in vitro models of NK
cell development using CD341 cord blood HPCs cul-
tured with stromal cells [4,23,26]. Thus, the overallphenotype of N-NK cells is distinct from any previ-
ously described in vitro or in vivo NK cell subset.N-NK Cells have Cytotoxic Capacity and can
Secrete IFN-g
Among normal human NK cell subsets, the
CD56dim population has more cytotoxic activity than
the CD56bright population, whereas CD56bright cells
play an important role in secretion of IFN-g and other
inflammatory cytokines. In contrast to the immature
surface phenotype observed for N-NK cells, we consis-
tently noticed that N-NK cells began to lyse the OP9
stromal cells during the thirdweekof coculture, indicat-
ing the presence of cytolytic capability. To directly
demonstrate the functional capacity of N-NK cells,
cytotoxicity was measured by in vitro assays using the
human hematopoietic tumor cell lines K562 (erythro-
leukemia), RPMI-8226 (multiple myeloma [MM]),
andDaudi (Burkitt lymphoma; Figure 5A). N-NK cells
derived from Notch signaling via Jagged2, Delta1, and
Delta4 demonstrated similar levels of cytotoxicity.
Biol Blood Marrow Transplant 15:1026-1037, 2009 1033Notch Ligands and Human NK Cell DifferentiationRPMI-8226 cells express high levels of surface MHC
class I molecules, whereas K562 and Daudi do not
(data not shown), indicating that the cytotoxic activity
of N-NK cells is not inhibited by tumor cell expression
ofMHCclass I.This is not surprising, given theabsence
of KIR and CD94/NKG2A expression by
N-NK cells. The cytotoxic ability of N-NK cells was
dependent on perforin, as the addition of the perforin
inhibitor concanamycin-A abrogated cytotoxic activity
against K562 cells (Figure 5B). N-NK cells displayed
moderate perforin expression by flow cytometry
(Figure 5C) andmorphologic assessment ofN-NKcells
by lightmicroscopy demonstrated the presence of cyto-
plasmic granules, consistent with a large granular lym-
phocyte morphology (not shown). We also tested the
cytotoxic function of NK cells from control cocultures
withoutNotch ligand, after enriching theseNK cells to
percentages .50% by negative cell selection.Figure 5. N-NK cells have perforin-dependent cytotoxic activity. (A) Cytoto
K562 and RPMI-8226 but not Daudi. N-NK cells from week 3 or 4 of cocultu
K562 cells is abrogated in the presence of the perforin inhibitor concanamy
week 4 of Delta4 coculture express perforin by flow cytometry; N-NK cells fro
(not shown). (D) The level of cytotoxic activity of Delta4-derivedN-NK cells is
than unstimulated PB NK cells (PB). PB NK cells were activated by overnight in
are shown.The cytotoxic function of NK cells developed in the
absence of Notch ligand was similar to that of
N-NK cells: when compared side by side, the average
percent specific lysis for K562 cells was 45.7% for NK
cells grown in the presence of Delta4 versus 50.1%
for NK cells grown in the absence of Notch ligand
(E:T ratio of 7:1), and 34.2% versus 28.5%, respec-
tively, for killing of RPMI-8226 cells (E:T ratio of 7:1).
We next compared the cytotoxic function of
N-NK cells with PB NK cells, either unstimulated
or activated overnight with IL-15 (10 ng/mL). Inter-
estingly, the killing activity of N-NK cells against
K562 and RPMI-8226 was similar to activated PB
NK cells (Figure 5D), whereas only activated PB NK
had activity against Daudi cells. This was in contrast
to unstimulated PB NK (cultured overnight without
IL-15), which had the lowest capacity of the 3 types
of NK cells for killing of K562, RPMI-8226, or Daudi.xicity assays demonstrate activity against the human leukemia cell lines
re were used as effector cells. (B) N-NK cell cytotoxicity assay against
cin-A (CMA). The Effector:Target ratio is 10:1. (C) N-NK cells from
m Jagged2 and Delta1 cultures have similar levels of perforin expression
similar, but not identical, to activated PBNK cells (PB Stim), and is greater
cubation with IL-15 (10 ng/mL). Averages of 3 independent experiments
Figure 6. Both N-NK cells and NK cells developed in the absence of
Notch ligand can secrete IFN-g only after overnight incubation with
IL-12 and IL-18 (100 ng/mL each). Levels of IFN-g secreted by PB NK
cells from 3 different healthy donors are shown for comparison. PB
NK cells were cultured for 2 days in the presence of IL-15, with or with-
out additional IL-12 and IL-18 on day 2.
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against Daudi cells, the killing activity of 2 other cell
lines was more similar to that of stimulated PB NK
cells than unstimulated.
To evaluate the ability of N-NK cells to secrete
cytokines, IFN-g in coculture supernatants was mea-
sured by standard ELISA. In the absence of IL-12
and IL-18, neither NK cells developed in the absence
or presence ofNotch signaling secreted IFN-g, similar
tomost PBNKcells cultured in IL-15 alone (Figure 6).
However, overnight incubation with IL-12 and IL-18
resulted in secretion of IFN-g by bothN-NK cells and
NK cells, developed in the absence of Notch ligand
(Figure 6), albeit at lower levels than IL-15-activated
PB NK cells further stimulated with IL-12 and IL-18.
Overall, these data indicate that although the sur-
face phenotype of N-NK cells resembles that of an
immature NK cell precursor (CD56bright, CD1171,
CD162, CD942, KIR2, CD11b2), the N-NK cells
have the functional characteristics of both CD56bright
and CD56dim NK cells, that is, cytokine secretion
and cytotoxic ability, respectively, with the cytotoxic
capacity ofN-NK cells being similar, but not identical,
to activated PB NK cells.DISCUSSION
Our data demonstrate that Notch receptor signal-
ing via specific Notch ligands (ie, Jagged2, Delta1, or
Delta4) in human CD341HPCs accelerates the devel-
opment of functional NK cells in vitro. Although the
data we show here uses CD341 HPCs isolated from
UCB, Notch-induced NK cell differentiation was
also seen in cocultures using BM-derived CD341
HPCs (data not shown). This study is the first to delin-
eate the differential ability of individual Notch ligands
to promote human NK cell differentiation, whereas at
the same time demonstrating a cytotoxic capacity of
N-NK cells, which is similar, although not identical,
to that of activated NK cells from PB. Thus, our
data raise the interesting possibility that Notch signal-
ing could be used to generate large numbers of func-
tional NK cells for cell therapy purposes, especially
because N-NK cells lack both KIR and NKG2A and
therefore would not be expected to be inhibited by pa-
tient class I MHC. Overcoming the inhibitory signals
transmitted by MHC-recognizing receptors is an im-
portant stratagem in the use of cytotoxic NK cells as
therapy against different types of malignancy [19].
The comparison of individual Notch ligands in
hematopoietic stem cell development has important
clinical applications, as purified recombinant Notch
ligand (specifically Delta1) is currently being investi-
gated as a means for cell expansion in the context of
hematopoietic stem cell transplantation (HSCT) [27-
29]. Our data demonstrate that in addition to Delta1,
both Jagged2 and Delta4 are able to promote humanNK cell differentiation, with Jagged2 and Delta4 act-
ing at a greater capacity than Delta1 with respect to
NK cell expansion. These findings suggest that further
investigation into the clinical use of recombinant
Jagged2 or Delta4 in hematopoietic cell culture/
expansion systems is warranted.
Our findings are in agreement with recent studies
showing Jagged2 induction of NK cells from murine
HPCs [17] and Delta1 induction of cytoplasmic
CD31 NK cells from human HPCs [18]. All these
studies corroborate the finding that Notch signaling
via Delta ligands promotes development of a common
T/NK precursor from human HPCs, at the expense of
B cell development [14], whereas our data are also con-
sistent with the preferential interaction of Delta4 with
Notch1, versus Delta1 [12]. Interestingly, in the pres-
ent system, the addition of IL-15 in the coculture com-
pletely abrogated the development of T cells and
subverted the common T/NK precursor to an exclu-
sively NK cell fate. Thus, the regulation of lymphocyte
development by Notch signaling in vitro is highly
dependent upon the cell culture environment.
Compared to the development of B andT cells, the
development ofNKcells is onlymarginally understood.
The growth factor that is essential forNK cell differen-
tiation is IL-15, although FLT3 ligand and c-KIT
ligand may also contribute [8]. NK cells can develop
in vitro from human or mouse HPCs without contact
with BM stromal cells, in the presence of cytokines
alone [30,31]. Culture with stromal cells, however, al-
lows for further maturation of NK cells in vitro, indi-
cated by acquisition of Ly49 receptors (in mouse cells)
[10] or KIRs (human) [9]. NK cell development in
vivo was traditionally postulated to occur in the BM,
because both murine and human marrow-derived
HPCs differentiate into NK cells in vitro [23,30,31].
However, recent evidence indicates that NK cells may
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lymph nodes, to which CD341 HPCs migrate from
the BM [3]. Nodal CD341 HPCs have the capacity to
differentiate into CD56bright NK cells, which are
more abundant in lymph nodes than the CD56dim sub-
set [3,7]. The development of NK cells in secondary
lymphogenous tissue has recently been divided into 4
stages: CD341CD1172CD942 (stage I), CD341
CD1171CD942 (stage II), CD342CD1171CD942
(stage III), and CD342CD1171/2CD941 (stage IV)
[4]. Subsequent maturation of CD56bright NK cells to
CD56dim NK cells (stage V) is postulated to occur in
the periphery.
A defined role for Notch signaling in NK cell
development has not been elucidated. The existence
of normal numbers of NK1.11 cells in mice having an
inducible knock-out of Notch1 indicates that this
particular receptor is not required forNK cell develop-
ment [16], although signaling via other Notch
receptorsmay have compensated for the lack ofNotch1
in this model. The ability to generate NK cells from
HPCs in stromal-free culture [30,31] indicates that
Notch signaling is not an absolute requirement for
HPCcommitment toNKcells. It is interesting to spec-
ulate that the additional NK cell maturation seen with
cocultured stromal cells [9,10] may involve signaling
via Notch ligands expressed by stromal cells, especially
because constitutively activated Notch signaling could
replace the need for stromal cells in supportingNK cell
differentiation in a recent study [32]. Preliminary data
from our lab also indicate thatNotch signaling acceler-
ates NK cell differentiation from CD341UCB cells in
the absence of a supporting stroma (not shown).
Notch signaling may also be important for mature
NK cell function. Gene profiling studies indicate that
both CD56dim and CD56bright NK cells express both
Notch1 and Notch2. Expression of both receptors is
2-3-fold higher in CD56bright cells [25], suggesting
that Notch may play a role in NK cell subset matura-
tion and/or function. Interestingly, murine NK cells
exhibit enhanced cytokine expression and cytotoxic
function in response to signaling from tumor cells or
dendritic cells transduced with Jagged2, indicating an
ability of Notch signaling to influence mature murine
NK cell function [33]. NK cell precursors and subsets
would be expected to encounter Notch signaling in
secondary lymphogenous organs, as human Delta4 ex-
pression is detectable in lymph node tissue [34] and
Delta1 is expressed in the spleen, where it is essential
for marginal zone B cell development [35]. Thus,
Notch signaling in vivo may have distinct effects on
NK cells at different stages of development.
The data from our coculture system indicate that
Notch is capable of inducing NK cell differentiation
from human HPCs, with maturation to the level of
the stage III NK precursor postulated by Freud et al.
[4]. The phenotype of N-NK cells differs slightly,however, from the observed phenotype of stage III
NK precursors, which do not express NKp30,
NKp46, or NKG2D [5]. In addition, the cytotoxic
and cytokine-secreting capabilities of N-NK cells are
not characteristic of stage III NK precursors, which
do not express perforin, exhibit cytotoxic activity, or
secrete IFN-g [4]. Instead, the functionality of the
N-NK cells in conjunction with their immature sur-
face phenotype resembles the ‘‘pseudomature’’ NK
cell that develops in vitro in the presence of IL-15;
the ‘‘pseudomature’’ term being a reference to the
observation that these NK cells have cytotoxic activity,
yet are CD56bright and negative for KIR [8].
Interestingly, in comparison to N-NK cells, NK
cells that developed after 4 weeks of culture in the ab-
sence of Notch ligand (OP9-Ret-10 culture) expressed
higher levels of CD16, CD94, and CD11b (Mac-1)
and lower levels of CD117, a phenotype more consis-
tent with transition to a stage IVNK cell. This implies
that although Notch signaling in the coculture system
accelerates differentiation of CD341 HPCS along an
NK cell path, the resulting NK cell may be fated to
a developmentally immature state. We did not observe
significantly increasing levels of CD94 or CD16
expression in N-NK cells between weeks 4-6 of cul-
ture, at which time the N-NK cells ceased to prolifer-
ate and overall cell numbers declined (data not shown),
indicating that further maturation of N-NK cells did
not occur after week 4 in this system.
A recent study using constitutively activated
Notch1 signaling in CD341 UCB cells also demon-
strated immature development of NK cells which
was dependent on Notch signaling [32]. However, in
this study the NK cells appeared hypofunctional com-
pared to NK cells developed in vitro in the absence of
Notch signaling, with decreased production of IFN-g
and decreased cytotoxicity against K562 cells. This is
in contrast to our results, which indicate similar cyto-
toxic activity and levels of IFN-g production between
NK cells developed in the presence or absence of
Notch signaling. These differences are likely because
of variable levels of Notch signaling between the 2 sys-
tems, and suggest that in our system, Notch signaling
may be downregulated during the coculture period,
thus producingNK cells distinct from those developed
in the presence of continuous Notch activation.
Continuous Notch activation may thus prevent full
maturation of developing NK cells.
Although Jagged2 and Delta4 were more robust
than Delta1 at inducing expansion of NK cells from
CD341 HPCs, the surface phenotype and purity of
the N-NK cells derived from each ligand-culture
system were comparable. These observations suggest
that Notch signals contributing to hematopoietic cell
expansion may be distinct from signals that cause
NK cell differentiation and/or maturation. Notch-
induced cell expansion in our cultures may occur at
1036 Biol Blood Marrow Transplant 15:1026-1037, 2009R. C. Beck et al.the level of the CD341 HPCs, as several studies have
demonstrated the ability of Notch signaling to expand
human UCB HPCs [28,34,36]. Indeed, data from 1
study suggest that Delta4 is more effective in expand-
ing CD341CD382Lin2 HPCs compared to Delta1
[34], consistent with our observations with respect to
NK cell expansion.
Although a definitive role for in vivo Notch signal-
ing in NK cell differentiation and maturation remains
unclear, the observed phenotype and cytotoxic capac-
ity of in vitro-derived N-NK cells suggests their
potential use as cell therapeutic agents. The infusion
of allogeneic NK cells as cell therapy in both solid
tumor and hematologic malignancy is an active area
of investigation. A Phase I trial examining the safety
of allogeneic NK cell infusion demonstrated the feasi-
bility of this procedure as well as a distinct lack of
donor NK cell-mediated graft-versus-host disease
(GVHD) [20]. The lack of GVHD in this trial is in
sharp contrast to the incidence of GVHD following
the current clinical practice of donor lymphocyte
infusion (DLI) after hematopoietic stem cell transplan-
tation (HSCT), where significant acute GVHD
(aGVHD) and/or chronic GVHD (cGVHD) develops
in up to half of the treated patients [37]. In addition,
data from haploidentical HSCT patients indicate that
donor ‘‘alloreactive’’ NK cells, which lack MHC class
I inhibitory signals because of KIR:MHC mismatch
with recipient cells, may prolong survival in leukemia
patients [38-40]. The prolonged survival in HSCT pa-
tients having donor KIR:recipient MHC mismatch is
likely, in part, because of to a direct antileukemic effect
of alloreactiveNK cells.Mousemodels ofHSCTdem-
onstrated that alloreactive NK cells may also act as BM
conditioning agents and may protect against GVHD
by the killing of host dendritic cells [38].
The cytotoxic activity ofN-NK cells against tumor
cell lines, which is comparable (although not identical)
to activated PBNK cells, indicates that these cells may
act as an antitumor agent if infused into patients. NK
cell recognition and killing of hematologicmalignancy,
carcinomas, and neural tumors is dependent in part
upon the activating receptors NKG2D, DNAM-1,
and/or the natural cytotoxicity receptors [41-46], all of
which are expressed by N-NK cells. However, N-NK
cells would not be capable of antibody-dependent
cell-mediated cytotoxicity, which is important in the
activity of therapeutic antibodies, because these cells
do not express notable levels of CD16. Interestingly,
the lack of expression of KIR and NKG2A by N-NK
cells predicts that these cells should be universally
alloreactive, that is, not inhibited by recipient MHC,
regardless of HLA type. This would result in an ease
of administration of such cells, if matching (or, more
precisely, mismatching) of donor and recipient HLA
could be avoided. In addition, because N-NK cells
can be derived from CD341 UCB cells, donor avail-ability and risk areminimal issues, versus the collection
of PBNK cells from adult donors via apheresis.We an-
ticipate that further studies will elucidate the clinical
potential for NK cells generated and expanded in vitro
using Notch signaling.ACKNOWLEDGMENTS
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